K-Bio Highlights Next-Generation Obesity and Metabolic Disease Drug Achievements at ADA in the US
Hanmi Pharmaceutical, Dong-A ST, Protinut, and Others Participate
Korean pharmaceutical and biotech companies have demonstrated their global competitiveness by unveiling a range of cutting-edge research results in the obesity and metabolic disease fields at the American Diabetes Association (ADA), the largest academic event in the sector.
According to the industry on June 10, Hanmi Pharmaceutical presented preclinical results for its novel obesity drug candidate HM17321 in a poster session. HM17321 is a urocortin 2 analog that targets the corticotropin-releasing factor receptor 2 (CRF2), rather than conventional incretin receptors. In animal models, co-administration with an amylin analog led to a reduction in body fat by up to 56.5% compared to pre-administration levels, while lean body mass (muscle mass) increased by up to 22.1%. Hanmi Pharmaceutical, which has confirmed the potential to overcome the limitation of existing treatments that cause muscle loss during weight reduction, is positioning this compound as a core asset in its obesity drug pipeline and is aiming for commercialization by 2031.
Among the Korean companies participating in this year’s conference, Protinut was the only one to give an oral presentation, where it unveiled preclinical results for its long-acting gastric inhibitory polypeptide receptor (GIPR) antagonist antibody pipeline, PRT-1309. Developed as a cross-reactive antibody that binds to both humans and mice, this compound produced a dose-dependent weight loss effect after a single administration, with the effect maintained for four weeks. With a half-life of 20.3 days, it is being developed as a maintenance therapy that could be administered every three to six months. When administered in combination with semaglutide, it demonstrated a maximum weight loss effect of 26.8%.
Dong-A ST presented clinical results for its SGLT-2 inhibitor DA-2811, as well as research data for its dual GLP-1 (glucagon-like peptide) and glucagon agonist obesity treatment DA-1726 and its MASH (metabolic dysfunction-associated steatohepatitis) treatment vanoglifel, suggesting the potential for combination therapies. HK inno.N announced that ecnoglutide, introduced from its Chinese partner Sciwind Biosciences, showed superiority in a phase 2 comparative clinical trial against semaglutide. This drug is distinguished by its enhanced signaling selectivity, which increases both efficacy and safety.
Peptone reported research results for its injectable PT403, which is being developed as a once-monthly treatment for diabetes and obesity. In a mouse model with diet-induced obesity, groups administered the drug every two or three weeks showed about 30% weight loss at the four-week mark.
Korean pharmaceutical and biotech companies are focusing on ‘improving the quality of weight loss’ and ‘maximizing dosing convenience’ within their obesity and metabolic disease pipelines. Although existing GLP-1-based obesity treatments have demonstrated excellent weight loss effects, side effects such as simultaneous loss of muscle mass and the need for frequent dosing have been pointed out as limitations. In response, Korean companies are going beyond appetite-suppressing mechanisms to discover new targets that preserve or even increase muscle mass, and are focusing on enhancing treatment synergy through combination therapies. Efforts are also underway to extend drug half-lives to improve patient convenience.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An industry official commented, “In order to overcome the limitations of existing GLP-1 therapies, such as muscle loss and frequent dosing cycles, Korean companies are presenting various combination therapies and next-generation mechanisms, standing out on the global stage. With the results presented at this conference as a turning point, discussions on joint research and technology exports with multinational pharmaceutical companies are expected to accelerate.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.